Literature DB >> 10755352

Report on 59 patients with renal amyloidosis.

S Paydas1.   

Abstract

We studied a group of 59 patients with renal amyloidosis. Mean age (45 male, 14 female) was 33.05+/-13.04 years. All of the cases had secondary amyloidosis. The causes of secondary amyloidosis were as follows: familial Mediterranean fever (FMF) 18 (30.5%), pulmonary tuberculosis 12 (20.33%), chronic oseomyelitis 8 (13.55%), bronchiectasia 9 (15.25%), rheumatic diseases 4 (6.4%), Castleman's disease 1 (1.6%), unknown aetiology 7 (11.86%). Hypertension was detected in 15.3% of the cases. In patients with less than 20 ml/min creatinine clearance (Ccr) hypertension was found in 20%. Hypotension was detected in 6 patients and all of these cases had severe hypoalbuminaemia (<2.1 g/dl). Nephrotic range proteinuria (>3.5 g/day) was found in 75% of cases. Daily proteinuria was correlated with serum levels of albumin, total lipid and cholesterol, haematocrit and duration of disease. The mean Ccr was 51.03+/-40.60 ml/min. Twenty-nine per cent of patients had Ccr less than 20 ml/min. Renal, subcutaneous fat and rectal biopsies demonstrated amyloid in 100%, 20% and 57.6%, respectively, of patients tested. Patients with secondary amyloidosis were treated with colchicine in addition to the therapy of primary disease (in 6 patients). Nine patients died, and end-stage renal disease developed in 12 patients during four years of follow-up. Proteinuria disappeared or decreased in patients with secondary amyloidosis except secondary to collagen tissue disease, without advanced renal failure. Colchicine did not affect amyloid deposition in 2 patients with normal renal function and negative proteinuria, who were rebiopsied. It can be questioned that "Colchicine may have effect(s) for decrement on proteinuria". At least colchicine can be of use in secondary amyloidosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10755352     DOI: 10.1023/a:1007152320216

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Secondary amyloidosis (AA).

Authors:  M A Gertz
Journal:  J Intern Med       Date:  1992-12       Impact factor: 8.989

2.  Amyloidosis. Introduction and overview.

Authors:  R A Kyle
Journal:  J Intern Med       Date:  1992-12       Impact factor: 8.989

3.  Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever.

Authors:  A Livneh; D Zemer; B Siegal; A Laor; E Sohar; M Pras
Journal:  Nephron       Date:  1992       Impact factor: 2.847

4.  [Amyloidosis and inflammation of the calcified mitral valve in patients with chronic rheumatism].

Authors:  R V De Assis; M Grinberg; E A Lopes; L V Décourt; C E Corbett; F Pileggi; A D Jatene
Journal:  Arq Bras Cardiol       Date:  1988-12       Impact factor: 2.000

5.  Prevalence of hypertension in renal amyloidosis: correlation with clinical and histological parameters. A study of 56 patients and review of the literature.

Authors:  Z Bentwich; E Rosenmann; M Eliakim
Journal:  Am J Med Sci       Date:  1971-08       Impact factor: 2.378

Review 6.  Familial Mediterranean fever. A survey of 470 cases and review of the literature.

Authors:  E Sohar; J Gafni; M Pras; H Heller
Journal:  Am J Med       Date:  1967-08       Impact factor: 4.965

7.  Renal transplantation in 45 patients with amyloidosis.

Authors:  A Pasternack; J Ahonen; B Kuhlbäck
Journal:  Transplantation       Date:  1986-12       Impact factor: 4.939

8.  Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal.

Authors:  G Karsenty; A Ulmann; D Droz; F Carnot; J P Grünfeld
Journal:  Nephron       Date:  1985       Impact factor: 2.847

9.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

Review 10.  Factor-X deficiency in amyloidosis: a critical review.

Authors:  P R Greipp; R A Kyle; E J Bowie
Journal:  Am J Hematol       Date:  1981-12       Impact factor: 10.047

View more
  5 in total

1.  Cutaneous and Systemic Plasmacytosis Associated with Renal Amyloidosis.

Authors:  Taek Geun Lee; Woo Seok Jeong; Seung Hyun Moon; Hyun Hwangbo; Sook Kyung Lee; Dong Ryeol Lee; Tae Gwang Kwon
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

2.  A clinical evaluation of renal amyloidosis in the Japan renal biopsy registry: a cross-sectional study.

Authors:  Shinichi Nishi; Eri Muso; Akira Shimizu; Hitoshi Sugiyama; Hitoshi Yokoyama; Yukio Ando; Shunsuke Goto; Hideki Fujii
Journal:  Clin Exp Nephrol       Date:  2016-08-25       Impact factor: 2.801

3.  Renal amyloidosis due to pulmonary tuberculosis in a patient with Down syndrome.

Authors:  Ozan Ozkaya; M Sükrü Paksu; Kenan Bek; Levent Yildiz; Tunç Fişgin; Nevzat Gürmen; Filiz Karagöz
Journal:  Eur J Pediatr       Date:  2005-10-08       Impact factor: 3.183

4.  Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.

Authors:  Serhan Piskinpasa; Hadim Akoglu; Eyup Koc; Fatma Dogru; Ezgi Yenigun Coskun; Didem Turgut; Nihal Ozkayar; Ramazan Ozturk; Ali Riza Odabas; Fatih Dede
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

5.  Renal amyloidosis in Behçet's disease: clinicopathologic features of 8 cases.

Authors:  Kemal Kosemehmetoglu; Dilek Ertoy Baydar
Journal:  Int Urol Nephrol       Date:  2012-09-09       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.